- Home
- EMD vs CAPR Comparison
EMD vs CAPR Comparison
Compare EMD & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- CAPR
- Stock Information
- Founded
- EMD 2003
- CAPR 2005
- Country
- EMD United States
- CAPR United States
- Employees
- EMD N/A
- CAPR N/A
- Industry
- EMD Finance/Investors Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMD Finance
- CAPR Health Care
- Exchange
- EMD Nasdaq
- CAPR Nasdaq
- Market Cap
- EMD 587.9M
- CAPR 525.3M
- IPO Year
- EMD N/A
- CAPR N/A
- Fundamental
- Price
- EMD $9.86
- CAPR $9.49
- Analyst Decision
- EMD
- CAPR Strong Buy
- Analyst Count
- EMD 0
- CAPR 7
- Target Price
- EMD N/A
- CAPR $39.29
- AVG Volume (30 Days)
- EMD 248.5K
- CAPR 1.6M
- Earning Date
- EMD 01-01-0001
- CAPR 03-19-2025
- Dividend Yield
- EMD 10.25%
- CAPR N/A
- EPS Growth
- EMD N/A
- CAPR N/A
- EPS
- EMD N/A
- CAPR N/A
- Revenue
- EMD N/A
- CAPR $22,270,465.00
- Revenue This Year
- EMD N/A
- CAPR $34.33
- Revenue Next Year
- EMD N/A
- CAPR $246.72
- P/E Ratio
- EMD N/A
- CAPR N/A
- Revenue Growth
- EMD N/A
- CAPR N/A
- 52 Week Low
- EMD $7.85
- CAPR $3.52
- 52 Week High
- EMD $9.55
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- EMD 51.62
- CAPR 33.16
- Support Level
- EMD $9.76
- CAPR $12.64
- Resistance Level
- EMD $9.92
- CAPR $13.81
- Average True Range (ATR)
- EMD 0.09
- CAPR 1.17
- MACD
- EMD 0.00
- CAPR -0.23
- Stochastic Oscillator
- EMD 73.08
- CAPR 8.36
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management investment company. Its primary investment objective is to seek high current income and the secondary objective is to seek capital appreciation.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.